Companies: 10,795·Total market cap: $144.5T
Immunome, Inc.

Immunome, Inc.

IMNMNASDAQHealthcare● Active
$18.54
$-0.05(-0.24%)
Market Cap$1.8B
P/E Ratio
52W High$27.65
52W Low$7.96
Overview

Immunome, Inc. (IMNM) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

imnm · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Immunome, Inc. (IMNM) measures how much investors pay for each dollar of the company's trailing earnings. IMNM's current PE ratio of N/A is calculated by dividing its stock price of $18.54 by its TTM earnings per share of -$1.99.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-2.14
Based on 10 analysts
EPS (TTM)
-$1.99
TTM · diluted EPS
PEG Ratio
-0.33
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Immunome, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2018 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Immunome, Inc.
Immunome, Inc.You
IMNM
$1.8BN/A-$1.99
AbCellera Biologics Inc.
AbCellera Biologics Inc.
ABCL
$1.7BN/A-$0.49
Biohaven Ltd.
Biohaven Ltd.
BHVN
$1.2BN/A-$6.86
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
CLDX
$1.9BN/A-$3.89
Maze Therapeutics, Inc.
Maze Therapeutics, Inc.
MAZE
$1.3BN/A-$3.05
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc.
NTLA
$1.5BN/A-$3.81
Pharvaris N.V.
Pharvaris N.V.
PHVS
$2.2BN/A-$2.97

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-2.43
2024-12-31
FY2024
$-5.00
2023-12-31
FY2023
$-5.38
2022-12-31
FY2022
$-3.04
2021-12-31
FY2021
$-2.14
2020-12-31
FY2020
$-1.76
2019-12-31
FY2019
$-1.84
2018-12-31
FY2018
$-7.18

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Immunome, Inc. (IMNM) measures how much investors pay for each dollar of the company's trailing earnings. IMNM's current PE ratio of N/A is calculated by dividing its stock price of $18.54 by its TTM earnings per share of -$1.99.

PE Ratio = Stock Price ÷ EPS (TTM)
= $18.54 ÷ -$1.99 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

IMNM pe ratio · 6 questions

IMNM's current PE ratio is N/A as of 2026-06-08, based on a stock price of $18.54 and TTM EPS of -$1.99. Data sourced from Financial Modeling Prep via IMNM's SEC 10-K and 10-Q filings.

IMNM PE ratioWhat is IMNM PE ratioCurrent PE ratio of IMNMIMNM PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Immunome, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08